Table 1

Baseline characteristics of the entire study population (prematch) and matched pairs (postmatch)

PrematchPostmatch
AF groupCF groupP valueAF groupCF group
n=371n=356n=279n=279
Clinical characteristics
 Age, years55.5±6.555.7±67.20.9755.6±6.655.5±7.4
 Male329 (88.7)322 (90.4)0.44249 (89.2)252 (90.3)
 Prior myocardial infarction30 (8.1)41 (11.8)0.0927 (9.3)27 (9.3)
 Prior use of DAPT47 (12.7)40 (11.2)0.5527 (9.7)31 (11.1)
 Prior stroke17 (4.6)23 (6.5)0.2714 (5.0)14 (5.0)
History of heart failure50 (13.5)42 (11.8)0.5032 (11.5)36 (12.9)
 Atrial fibrillation12 (3.2)7 (2.0)0.287 (2.5)6 (2.2)
 Peripheral artery disease43 (11.6)36 (10.1)0.5226 (9.3)26 (9.3)
 Acute myocardial infarction97 (26.1)68 (19.1)0.0264 (22.9)61 (21.9)
 Unstable angina56 (15.1)60 (16.9)0.5145 (16.1)43 (15.4)
 Stable coronary artery disease218 (58.8)228 (64.0)0.14170 (60.9)175 (62.7)
Angiographic and procedural characteristics
 Numbers of stents used (per patient)1.61.670.361.591.59
 Drug-eluting stents use345 (93.0)322 (90.4)0.21255 (91.4)258 (92.5)
 Bare-metal stents use34 (9.3)36 (10.0)0.7432 (11.5)30 (10.8)
 Minimum stent diameter, mm (IQR)3 (2.5–3.5)3 (2.5–3.5)0.903 (2.5–3.5)3 (2.5–3.5)
 Total stent length, mm (IQR)29 (20–51)28 (20–52)0.8329 (20–51)28 (20–50)
 Fractional flow reserve30 (8.1)16 (4.5)0.0515 (5.4)15 (5.4)
Medications
 Aspirin348 (93.8)331 (93.0)0.66257 (92.1)256 (91.8)
 Thienopyridine367 (98.9)354 (99.4)0.44276 (98.9)277 (99.3)
 Cilostazole13 (3.5)10 (2.8)0.5910 (3.6)8 (2.9)
 Statins333 (89.8)307 (86.2)0.14248 (88.4)241 (86.4))
 ACE-I/ARB229 (61.7)214 (60.1)0.66169 (60.6)171 (61.3)
 Bata blockers187 (50.4)168 (47.2)0.39138 (49.5)137 (49.1)
 Calcium-channel blocker138 (37.2)147 (41.3)0.2698 (35.1)106 (38.0)
 Insulin/oral hypoglycaemic agents114 (30.7)110 (30.9)0.9689 (31.9)90 (32.3)
 Direct oral anticoagulant5 (1.3)5 (1.4)0.954 (1.4)3 (1.1)
 Warfarin15 (4.0)16 (4.5)0.7611 (3.9)13 (4.7)
 Proton pump inhibitor290 (78.2)265 (74.4)0.24213 (76.3)209 (74.9)
 H2 blocker25 (6.7)39 (11.0)0.0523 (8.2)22 (7.9)
Clinical follow-up
 Outpatient rehabilitation14 (3.8)12 (3.4)0.779 (3.2)8 (2.9)
 ECG349 (95.1)342 (95.0)0.95267 (95.7)263 (94.3)
 Exercise stress test131 (35.7)133 (36.9)0.73103 (36.9)101 (36.2)
 Echocardiography263 (71.7)243 (67.5)0.22192 (68.8)200 (71.7)
 Coronary CT angiography20 (5.4)49 (13.8)<0.00118 (6.5)28 (10.0)
 Cardiac MR6 (1.6)5 (1.4)0.815 (1.8)2 (0.7)
 Cardiac nuclear scan56 (15.1)38 (10.7)0.0838 (13.6)34 (12.2)
  • Values are expressed as mean±SD, n (%), or median (IQR).

  • AF, angiographic follow-up; ARB, angiotensin receptor blocker; CF, clinical follow-up; DAPT, dual antiplatelet therapy; H2 blocker, histamine type-2 receptor blocker.